Accurate Diagnostic Laboratories is set to launch its immunoglobulin class IgG and IgM antibody testing this week to help the US meet the demand for wider Covid-19 diagnostics.
The lab will initially use the Diazyme testing platform to offer the antibody test.
Earlier this month, Accurate Diagnostic and RUCDR Infinite Biologics developed new collection approach that uses saliva as the primary test biomaterial for Covid-19.
The method enables self-administered sample collection by individuals who are in quarantine or self-isolation.
With the launch of the new serology Covid-19 diagnostics test, the lab expects to meet both sides of the laboratory testing equation by diagnosing patients with active infection and those who have been infected before.
To continue scaling up its capacity to meet the testing demand in the local and national markets, Accurate Diagnostic is working with its vendor partners.
Accurate Diagnostic Laboratories CEO and owner Rupen Patel said: “While there is still a lot of scientific ambiguity on whether the detection of antibodies confirms that people exposed to Covid-19 have developed an immune response, most believe that antibody testing is a significant part of our fight against the virus.
“There is no playbook for handling this pandemic but I am extremely proud of the Accurate Diagnostic Labs family and all our colleagues in the industry for working tirelessly to do our part by expanding testing.”
Recently, Diazyme has launched Diazyme DZ-Lite SARS-CoV-2 IgG and SARS-CoV-2 IgM CLIA test kits for detecting Covid-19.
They are run on the fully automated Diazyme DZ-Lite 3000 Plus chemiluminescence analyser that Accurate Diagnostics will also use for its immunoglobulin class IgG and IgM antibody testing.